Last edition
News about Global Pharma
Conduit and Agility to Develop Enhanced Formulations for its Autoimmune Pipeline
Conduit has developed a series of novel, advantageous solid forms of all its autoimmune pipeline assets, each protected by newly established composition-of-matter intellectual property (IP).
Global Pharma | 23/01/2025 | By Aishwarya | 535
Emcure Pharmaceuticals Launches its R&D Centre in Ahmedabad
The Emcure Research Centre (ERC) is strategically designed to enable breakthroughs in complex drug delivery systems, such as sustained-release formulations, liposomal injections and advanced dermal therapies.
Global Pharma | 23/01/2025 | By Aishwarya | 994
Syntegon Welcomes Eros Carletti as New Chief Financial Officer
Eros Carletti succeeds Dr. Peter Hackel, who left Syntegon on December 31, 2024, following two successful years as CFO.
Global Pharma | 23/01/2025 | By Aishwarya | 434
Strides Pharma Science Ltd. achieved a debut ESG score of 76/100 and a CSA score of 75/100 in S&P Global’s Corporate Sustainability Assessment. Strides has secured a position in the 94th percentile among its peers in the DRG Global Pharmaceuticals industry.
Global Pharma | 22/01/2025 | By Manvi | 234
Pharma Industry's Wishlist for Budget 2025: Key Expectations
The forthcoming Union Budget 2025 presents a pivotal opportunity for the Indian pharmaceutical sector to address existing challenges and pave the way for sustainable growth.
Global Pharma | 22/01/2025 | By Aishwarya | 1082
Hoth Therapeutics Announces Acquisition of New Patent Applications
Hoth Therapeutics continues to invest in robust research and development strategies, ensuring the protection and growth of its proprietary technologies.
Global Pharma | 22/01/2025 | By Aishwarya | 372
Strides Secures USFDA Approval for Acetaminophen and Ibuprofen Tablets, 125 mg/250 mg
Strides Pharma Science Ltd.'s subsidiary, Strides Pharma Global Pte. Ltd., has received USFDA approval for Acetaminophen and Ibuprofen Tablets (OTC), a dual-action pain relief product bioequivalent to Advil Dual Action.
Global Pharma | 21/01/2025 | By Manvi | 334
Cormica Acquires Zwisler Laboratorium to Expand European Business
This landmark acquisition marks Cormica’s first entry into the German market, a key milestone in its strategy to expand its European footprint.
Global Pharma | 21/01/2025 | By Aishwarya | 250
ReciBioPharm Bags Three Year Grant to Advance RNA Manufacturing
The funding will support the global deployment of xRNA Continuous Manufacturing technologies to LMICs with a strong focus on the development of state-of-the-art inline PAT capabilities and predictive analytics software.
Global Pharma | 21/01/2025 | By Aishwarya | 311
Kincell Bio Appoints New Chief Executive Officer to Drive Business Growth
Mark, who has served as Chair of the Board since May 2024, brings decades of industry experience to the role and will be pivotal in advancing Kincell Bio’s mission to support innovators in the rapidly growing cell therapy sector.
Global Pharma | 21/01/2025 | By Aishwarya | 264
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy